Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002374 · ClinicalTrials.gov registry record · Phase 3
A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT00002374 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 120 participants.
The verdict
NCT00002374, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
To examine the efficacy of saquinavir SGC (soft gel capsules) in combination with other antiretrovirals in HIV-1 infected patients currently treated with saquinavir HGC (hard gel capsules) measured by the absolute change in plasma HIV-1 RNA during the 24 weeks of study treatment.
Interventions
- DRUG Ritonavir
- DRUG Stavudine
- DRUG Nelfinavir mesylate
- DRUG Saquinavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002374
The ClinicalTrials.gov registry entry for NCT00002374 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ritonavir is the first listed.
NCT00002374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002374 about?
NCT00002374 is a clinical study titled "A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients". To examine the efficacy of saquinavir SGC (soft gel capsules) in combination with other antiretrovirals in HIV-1 infected patients currently treated with saquinavir HGC (hard gel capsules) measured by the absolute change in plasma HIV-1 RNA during the 24 weeks of study treatment.
What is the current status of trial NCT00002374?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants.
What interventions are being tested in trial NCT00002374?
The interventions under investigation include: Ritonavir (DRUG), Stavudine (DRUG), Nelfinavir mesylate (DRUG), Saquinavir (DRUG).
Who is sponsoring clinical trial NCT00002374?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.